These findings highlight the distinct mechanisms of E/I imbalance associated with Aβ and tau pathology and the potential of targeting specific manifestations to enable precise therapeutic interventions to improve cognitive outcomes in AD. The gene discussed is MAPT; the disease is Alzheimer disease.